Efficacy
References
1. Pitcairn G et al. J Aerosol Med 2005;3:264-272.
2. Anderson A. Int J Chron Obstruct Pulmon Dis 2006;1:251-259.
3. Dalby R et al. Med Devices: Evidence and Research 2011;4:145-155.
MPR-PH-100304
Production date: April 2022
Production date: April 2022
What is Tiotropium + Olodaterol HCl (Spiolto® Respimat®)?
Tiotropium bromide + Olodaterol HCl (Spiolto® Respimat®) is indicated for the long term, once- daily maintenance treatment in patients with COPD (including chronic bronchitis and emphysema), to reduce airflow obstruction, to improve quality of life, to reduce associated dyspnoea, to improve.
Tiotropium + olodaterol is administered via Respimat®, the only inhaler available that actively delivers a unique mist, meaning a person just needs to take a slow deep breath to get the medication deep into the lungs.*[5-9]
Tiotropium + olodaterol is administered via Respimat®, the only inhaler available that actively delivers a unique mist, meaning a person just needs to take a slow deep breath to get the medication deep into the lungs.*[5-9]
What is the safety profile of Tiotropium + Olodaterol HCl (Spiolto® Respimat®)?
Tiotropium bromide + Olodaterol HCl (Spiolto® Respimat®) has a comparable adverse event profile to the component monotherapies.[10]
Tiotropium bromide + Olodaterol HCl (Spiolto® Respimat®) safety and tolerability profile was established in patients treated for up to 52 weeks.[10]
The proportion of patients who discontinued due to adverse events with Tiotropium + Olodaterol (Spiolto® Respimat®) was comparable to that of Tiotropium (SPIRIVA®) and Olodaterol (STRIVERDI®).[10]
The percentage of patients reporting an adverse event with Tiotropium + Olodaterol (Spiolto® Respimat®) was comparable to that of Tiotropium (SPIRIVA®).[10]
Most adverse events were mild to moderate with no new safety risks seen beyond the effects of the monocompounds.[4],[10-12]
For full safety profile, please refer to the local prescribing information
What are the contraindications of Tiotropium + Olodaterol HCl (Spiolto® Respimat®)?[4]
Tiotropium + Olodaterol (Spiolto® Respimat®) is contraindicated in patients with hypersensitivity to tiotropium, atropine or its derivatives, e.g. ipratropium or oxitropium, olodaterol, or any component of this product.
For information on warnings and precautions please refer to the local prescribing information
Tiotropium bromide + Olodaterol HCl (Spiolto® Respimat®) safety and tolerability profile was established in patients treated for up to 52 weeks.[10]
The proportion of patients who discontinued due to adverse events with Tiotropium + Olodaterol (Spiolto® Respimat®) was comparable to that of Tiotropium (SPIRIVA®) and Olodaterol (STRIVERDI®).[10]
The percentage of patients reporting an adverse event with Tiotropium + Olodaterol (Spiolto® Respimat®) was comparable to that of Tiotropium (SPIRIVA®).[10]
Most adverse events were mild to moderate with no new safety risks seen beyond the effects of the monocompounds.[4],[10-12]
For full safety profile, please refer to the local prescribing information
What are the contraindications of Tiotropium + Olodaterol HCl (Spiolto® Respimat®)?[4]
Tiotropium + Olodaterol (Spiolto® Respimat®) is contraindicated in patients with hypersensitivity to tiotropium, atropine or its derivatives, e.g. ipratropium or oxitropium, olodaterol, or any component of this product.
For information on warnings and precautions please refer to the local prescribing information
References
[1] Maltais F et al. Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD. Thorax 2014;69:A186-A187
[2] Ferguson F et al. Efficacy of tiotropium+olodaterol in patients with COPD by initial disease severity and treatment intensity: a post hoc analysis. Adv Ther. 2015; 32(6): 523-526
[3] Singh D et al. Tiotropium+olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015; 10: 1312-1319
[4] Tiotropium+Olodaterol (Spiolto® Respimat®) Philippines Prescribing Information, 23 March 2020.
[5] Newman SP et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: Comparison of Respimat® with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113: 957-963
[6] Pitcairn G et al. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ Inhaler compared to deposition by metered dose inhaler or by Turbuhaler® dry powder inhaler. J Aerosol Med 2005; 18(3): 264-272
[7] Dalby R et al. A review of the development of Respimat® Soft Mist™ Inhaler. Int J Pharm 2004; 283: 1-9
[8] Dalby RN et al. Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl) 2011; 4: 145-155
[9] Anderson P. Use of Respimat® Soft Mist™ Inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2006; 1(3): 251–259
[10] Buhl R, et al. Eur Respir J. 2015;45:969-979.
[11] Tiotropium (Spiriva Respimat) Philippines Prescribing Information 23 March 2020.
[12] Olodaterol (Striverdi Respimat) Philippines Prescribing Information 150708.
[1] Maltais F et al. Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD. Thorax 2014;69:A186-A187
[2] Ferguson F et al. Efficacy of tiotropium+olodaterol in patients with COPD by initial disease severity and treatment intensity: a post hoc analysis. Adv Ther. 2015; 32(6): 523-526
[3] Singh D et al. Tiotropium+olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015; 10: 1312-1319
[4] Tiotropium+Olodaterol (Spiolto® Respimat®) Philippines Prescribing Information, 23 March 2020.
[5] Newman SP et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: Comparison of Respimat® with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113: 957-963
[6] Pitcairn G et al. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ Inhaler compared to deposition by metered dose inhaler or by Turbuhaler® dry powder inhaler. J Aerosol Med 2005; 18(3): 264-272
[7] Dalby R et al. A review of the development of Respimat® Soft Mist™ Inhaler. Int J Pharm 2004; 283: 1-9
[8] Dalby RN et al. Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl) 2011; 4: 145-155
[9] Anderson P. Use of Respimat® Soft Mist™ Inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2006; 1(3): 251–259
[10] Buhl R, et al. Eur Respir J. 2015;45:969-979.
[11] Tiotropium (Spiriva Respimat) Philippines Prescribing Information 23 March 2020.
[12] Olodaterol (Striverdi Respimat) Philippines Prescribing Information 150708.
